Paul Tudor Jones Blueprint Medicines Corp Transaction History

Tudor Investment Corp Et Al

$26.8 Billion
Q3 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 7,500 shares of BPMC stock, worth $825,375. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,500

Previous 3,700 102.7%

Holding current value

$825,375

Previous $398,000 74.12%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$37.97 - $50.0 $366,904 - $483,150	9,663 New	9,663 $435,000
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $481,275 - $748,950	9,639 Added 51.26%	28,444 $1.87 Million
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $393,501 - $610,305	8,700 Added 86.1%	18,805 $950,000
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $121,887 - $248,010	2,253 Added 28.69%	10,105 $646,000
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $292,929 - $360,496	-3,108 Reduced 28.36%	7,852 $841,000
Q3 2021 Nov 15, 2021	SELL	$80.98 - $109.47 $5.69 Million - $7.7 Million	-70,299 Reduced 86.51%	10,960 $1.13 Million
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $6.73 Million - $8.21 Million	81,259 New	81,259 $7.15 Million
Q1 2018 May 15, 2018	SELL	$73.28 - $102.95 $775,448 - $1.09 Million	-10,582 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $422,503 - $593,157	6,716 Added 173.72%	10,582 $798,000
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $163,802 - $269,344	3,866	3,866 $269,000

Others Institutions Holding BPMC

# of Institutions

350

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.57B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account